ARTICLE | Financial News
Verastem planning follow-on
July 16, 2013 11:51 PM UTC
Cancer stem cell company Verastem Inc. (NASDAQ:VSTM) proposed a follow-on late Tuesday underwritten by Jefferies and Leerink. Verastem's VS-6063 is in a Phase I/Ib trial to treat advanced ovarian cancer, with Phase II trials in mesothelioma and non-small cell lung cancer (NSCLC) slated to start this quarter. The company has exclusive, worldwide rights to the inhibitor of focal adhesion kinase (FAK) targeting cancer stem cells from Pfizer Inc. (NYSE:PFE). ...